Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2023.05.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper.
ESC Heart Fail
September 2025
Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Atrial functional mitral regurgitation (AFMR) is an increasingly recognized subtype of mitral regurgitation, characterized by left atrial remodelling and mitral annular dilation in the absence of primary mitral valve disease or left ventricular dysfunction. Closely linked to chronic atrial fibrillation and heart failure with preserved ejection fraction, AFMR is associated with poor clinical outcomes and represents a growing therapeutic challenge. This expert opinion paper summarizes current evidence on the epidemiology, pathophysiology, diagnosis and management strategies, including medical therapy and emerging data supporting surgical and transcatheter interventions in selected patients.
View Article and Find Full Text PDFTMVR for the Treatment of Mitral Regurgitation: A State-of-the-Art Review.
Circ Cardiovasc Interv
September 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy (F.T., G.A., M.G., K.S., D.D., G.S., M.C.).
Mitral regurgitation is the most common valve disease worldwide. Despite its wide success in inoperable or high-risk surgical patients, transcatheter edge-to-edge repair remains limited by some anatomic features and the not negligible rate of significant residual regurgitation. Transcatheter mitral valve replacement has emerged as a viable alternative that promises to overcome these issues, but its development has been progressing slowly.
View Article and Find Full Text PDFTranscatheter Tricuspid Valve Interventions to Manage Tricuspid Regurgitation: A Narrative Review.
Rev Cardiovasc Med
August 2025
Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Medical devices for tricuspid regurgitation have emerged as viable treatment options for patients who do not respond to drug therapy or who are unsuitable for open-heart surgery due to high surgical risk. Recently, numerous new medical devices have been proposed and approved for use. Therefore, comprehensive reviews of the literature on the current medical devices for tricuspid regurgitation are necessary.
View Article and Find Full Text PDFClinical Utility of Transcatheter PFO Exploration in Cryptogenic Stroke Patients With Negative TEE but High Suspicion of PFO-Related Etiology.
Catheter Cardiovasc Interv
September 2025
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Patent foramen ovale (PFO) has been identified as a potential risk factor for cryptogenic stroke (CS). Although transesophageal echocardiography (TEE) is considered the gold standard for PFO detection, false-negative results remain a clinical concern, particularly in CS patients with high suspicion of PFO-related etiology.
Aims: To evaluate the clinical utility of transcatheter PFO exploration (TPFOE) in CS patients with negative TEE findings but high suspicion of PFO-related etiology.
Long-term effect of transcatheter mitral valve edge-to-edge repair on left ventricular function and mitral regurgitation severity: a single-center experience.
Egypt Heart J
September 2025
Department of Cardiology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Background: Long-term outcomes of transcatheter mitral valve edge-to-edge repair (TEER) are compared with medical therapy remain under investigation. This study evaluated the 3-year effects of MitraClip on mitral regurgitation (MR) severity, ventricular remodeling, and clinical outcomes in high surgical-risk patients.
Methods: A single-center retrospective cohort included 31 MitraClip patients (2016-2023) and 30 contemporaneous controls on maximally tolerated guideline-directed medical therapy.